Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent
Authors
Alexander P. Bye (ORCID: https://orcid.org/0000-0002-2061-2253)
Michael Desborough (ORCID: https://orcid.org/0000-0002-1951-5616)
Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent
Alexander P. Bye, Michael Desborough, Neline Kriek, Sakthivel Vaiyapuri et al.
Journal
Haematologica
Topics
Platelet Disorders and Treatments
article
Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent
Alexander P. Bye, Michael Desborough, Neline Kriek, Sakthivel Vaiyapuri, Tanya Sage, Jonathan M. Gibbins, Gemma Little, Polly Whitworth, Ashifa Al Juwaiser, Joanne L. Mitchell
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
NHS Blood and Transplant (GB), John Radcliffe Hospital (GB), Oxford University Hospitals NHS Trust (GB), University of Reading (GB), University of Birmingham (GB)
Funders
British Heart Foundation, Rosetrees Trust, National Institutes of Health
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Recombinant von Willebrand Factor (vonicog alfa) reduces platelet inhibition caused by antiplatelet drugs and has potential as an acute haemostatic agent — Alexander P. Bye, Michael Desborough, et al. · Haematologica (2026) | TGRS Research Map | TGRS